Company Overview of Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc., a development-stage pharmaceutical company, develops treatments for smoking cessation, cocaine dependence, and other addictions. It engages in developing EMB-001, an addiction treatment that includes benzodiazepine oxazepam and cortisol synthesis inhibitor metyrapone medications, which targets the stress response system and specific brain functions that leads to craving and relapse associated with these disorders, as well as acts by modulating various stress-related pathways to reduce the craving that drives addictions. The company was founded in 2005 and is based in Sudbury, Massachusetts.
29 Babe Ruth Drive
Sudbury, MA 01776
Founded in 2005
Key Executives for Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc. Key Developments
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Embera NeuroTherapeutics, Inc., please visit emberaneuro.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.